Previous 10 | Next 10 |
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting, highlights recent clinical and regu...
NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics announced today that ELZONRIS (tagraxofusp) was the subject of preclinical dat...
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) is the subject of three clinica...
It is a principle of diplomacy that one must know something of the truth in order to lie convincingly ." - Tom Clancy, The Hunt for Red October Today, we revisit a small oncology name. Like most small biotech stocks (and the majority of the overall market), the shares have been under pres...
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) Phase 2 clinical data in chroni...
NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in blastic plasmacyt...
NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in chronic myelomono...
Stemline Therapeutics, Inc (STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Ivan Bergstein – Chief Executive Officer Robert Francomano – Senior Vice President Global Head of Commercial...
Stemline Therapeutics (NASDAQ: STML ): Q1 GAAP EPS of -$0.73 misses by $0.07 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the de...
News, Short Squeeze, Breakout and More Instantly...
Stemline Therapeutics Inc. Company Name:
STML Stock Symbol:
NASDAQ Market:
Stemline Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Franklin Financial Network, Inc. (NYSE: FSB ) r...
Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. That has intrepid investors wondering if their recent gains could be the beginning of something much larger. Data source: Yahoo! Finance. It isn't unusual to see small-cap...
NEW YORK , May 5, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ul...